Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-22
2011-03-22
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016800, C514S016900, C514S017100, C514S021200, C514S008800, C530S350000, C530S351000, C530S300000, C435S069100, C435S320100, C435S252300, C435S254110, C435S325000, C536S023100, C536S023500
Reexamination Certificate
active
07910552
ABSTRACT:
The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein (BMP), such as BMP-6, containing a heparin binding site and nucleotide molecules encoding the proteins and host cells expressing the proteins. The present invention relates also to the use of the bone morphogenetic protein for treating disorders related to bone and cartilage formation. The present invention further relates to osteogenic devices and pharmaceutical compositions containing the protein.
REFERENCES:
patent: 5106626 (1992-04-01), Parsons
patent: 5187076 (1993-02-01), Wozney et al.
patent: 5399677 (1995-03-01), Wolfman
patent: 5939388 (1999-08-01), Rosen
patent: 2003/0187232 (2003-10-01), Hubbell
patent: 200021106 (2000-01-01), None
patent: 762387 (2003-06-01), None
patent: 1 131 087 (2004-09-01), None
patent: WO 90/03733 (1990-04-01), None
patent: WO 90/11366 (1990-10-01), None
patent: WO 92/05199 (1992-04-01), None
patent: WO 93/00049 (1993-01-01), None
patent: WO98/51354 (1998-11-01), None
patent: WO 2005/089826 (2005-09-01), None
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 492-495.
European search report in corresponding EP 06743556, Feb. 2009.
Ruppert R et al.,“Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity”, European Journal of Biochemistry, vol. 237, No. 1, Apr. 1, 1996, pp. 295-302, XP000891887.
De Noronha Pissarra, P. Recombinant DNA Proteins for the Biopharmaceutical Industry and the Future forEscherichia Coli.Business Briefing Pharma Outsourcing 2004 [Online], Jan. 204, [Retrieved Aug. 8, 2008] Retrieved From the Internet <URL.
Database Uniprod [Online] Oct. 1, 2002, Bone Morphogenetic Protein 6 (Fragment,Equus caballus), Retrieved From UNIPROT/EBI.
Database Uniprot [Online] Feb. 1, 1995 “Bone Morphogenetic Protein 6 Precursor (Rattus norvegious)”.
Database NCBI/BENBANK Accession AAD27804 Apr. 27, 1999, Bone Morphogenetic Protein 7 Precursor.
Database EMBL EBI AC Q29607 Nov. 1, 1997, Bone Morphogenetic Pportein 4 Precursor BM -4 99% Identity With DEQ ID No. 1 in 116 AA Overlap (1-116:293-408) & Feng I.Q. et al Biochimica et Biophhysica ACTA.
Database EMBL EBL, AC Q 51419 May 10, 2005 Bone Morphogenetic Protein 4 Fragment 99% Identity With DEQ ID No. 1 in 116 AA Overlap 1-116 -274-389.
Database EMBL EBI AC Q8MJV5, Oct. 1, 2002 Bone Morphogenetic Protein 4 99% Identity With SEQ ID No. 1 In 116 AA Overlap 1-116:294-409.
Database EMBL EBL AC AAE44686 Feb. 14, 2001 Sequence 2 From Patent US 608690 98% Identity With SEQ ID No. 1 In 116 AA Overlap 1-116:293-408 & US 6083690 A (Harris et al.).
Database EMBL EBL AC AAE08202, Sep. 29, 1999, Sequence 4 From Patent US 5804416 98% Identity With SEQ ID No. 1 In 116 AA Overlap (1-116:I116.
Database EMBL EBL AC AX356001 Feb. 6, 2002, Sequence 2 From Patent WO 0192298 98% Identity With SEQ ID No. 1 In 116 AA Overlap (1-116:I116).
Database EMBL EBI, AC AX722049 May 7, 2003, Sequence 2 From Patent EPO 1298140.0 98% Identity With SEQ ID No. 1 In AA Overlap 1-116:I116N.
Database EMBL EBI AC AF 300813 Oct. 13, 2000, Rangifer Tarandus Tarandus Bone Morphogenetic Protein 3B MRNA, Parital ODS 95.6% Identity With SEQ ID No. 1 In 138 AA Overlap (1-138:304-440.
Database EMBL EBI AC:CS031978 Mar. 13, 2005 Sequence 1484 From Patent WO 2005016962 A2.
Database EMBL EBI, AC ADQ19527, Aug 26, 2004 Human Soft Tissue Sarcomaupregulated Preotein SEQ ID No.1 In 138 AA Overlap (1-138:341-478 & WO 2004048938 A2 (Protein Design Labs Inc).
Database EMBL EBI AC ADN39338 Jun. 17, 2004 Cancer/Angiogenesis /Fibroisis Related Polypeptide SEQ ID No. B22 9.3.5% Identity With SEQ ID No.1 In 138 AA Overlalp (1-138:341-478 & WO 03042661 A2.
Database EMBL EBI ACAAY92023 Jul. 19, 2000, Human Bone Morphogenetic Protein 3B BMP 3B.
Database EMBL EBI AC AA W06539 Mar. 12, 1997, Human Bone Morphogenetic Protein 10 93.5% Identity With SEQ ID No. 1 In 138 AA Overlap.
Database EMBL EBI AC AAR47587 Jul. 18, 1994 Rat Bone Formation Inducing Protein 93.5 Identity With SEQ ID No. 1 in 138 AA Overlap.
Database EMBL EBI AC ADH11577 Mar. 11, 2004 Human Bone Morphogenetic Proetein (BMP) Polypeptide #5, 93.5% Identity With SEQ ID No. 1 in 138 AA Overlap.
Birr Elli
Hietala Oili
Jalovaara Pekka
Juustila Marja
Korkala Heli
BBS-Bioactive Bone Substitutes Oy
Kemmerer Elizabeth C.
Young & Thompson
LandOfFree
Bone morphogenetic proteins containing a heparin binding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bone morphogenetic proteins containing a heparin binding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bone morphogenetic proteins containing a heparin binding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2633962